Horizons Ventures and OurCrowd led a $24m Series B round in SaNOtize.

Horizons Ventures, a venture capital firm, and OurCrowd, a venture investing platform, led a $24m Series B round in SaNOtize, an anti-infective-focused therapeutics company, with participation from ABC International. “We are thrilled to embark on these new partnerships, as they empower SaNOtize to accelerate its research program in various therapeutic fields and expand our Phase 3 NONS Covid-19 trial to additional countries. Our clinical and observational studies found NONS to be safe and effective at both treating and preventing Covid-19, even amid delta and omicron surges. We look forward to expanding our clinical research and working toward regulatory approval in the United States and Canada," Gilly Regev, SaNOtize Co-Founder and CEO.